Background and Discovery
Sermorelin, formally designated as sermorelin acetate (GHRH 1-29 NH2), is a synthetic peptide corresponding to the first 29 amino acids of the 44-amino acid endogenous human growth hormone-releasing hormone (GHRH). The native GHRH molecule was first characterised in the early 1980s following its isolation from pancreatic tumour tissue in patients presenting with ectopic acromegaly (Guillemin et al., 1982). Shortly thereafter, the hypothalamic form of GHRH was sequenced from human hypothalamic extracts, confirming the identity of the endogenous peptide responsible for stimulating pituitary growth hormone (GH) synthesis and secretion (Ling et al., 1984).
Structure-activity relationship studies demonstrated that the full biological activity of native GHRH(1-44) resides within the N-terminal 29-residue fragment. The truncated analogue retains complete receptor binding affinity and signal transduction capability, while exhibiting improved synthetic accessibility and pharmaceutical properties. Sermorelin was subsequently developed as a diagnostic and therapeutic agent, receiving regulatory approval in the United States for the evaluation of pituitary GH secretory capacity and the treatment of idiopathic growth hormone deficiency in paediatric populations (Prakash and Goa, 1999).
The peptide sequence (Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2) contains an amidated C-terminus, which confers marginal resistance to carboxypeptidase degradation compared with the free acid form. Nonetheless, the molecule remains susceptible to rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV), which cleaves the Ala2-Asp3 bond, representing a significant pharmacokinetic limitation that has driven the development of longer-acting GHRH analogues.
Mechanism of Action
GHRH Receptor Agonism
Sermorelin exerts its biological effects through high-affinity binding to the growth hormone-releasing hormone receptor (GHRH-R), a class B G protein-coupled receptor (GPCR) expressed predominantly on somatotroph cells of the anterior pituitary gland. Upon receptor engagement, sermorelin activates the Gs-adenylyl cyclase-cyclic AMP (cAMP) signalling cascade, resulting in elevation of intracellular cAMP concentrations and subsequent activation of protein kinase A (PKA).
PKA-mediated phosphorylation of downstream targets produces two principal physiological outcomes: the immediate exocytotic release of preformed GH granules from somatotroph secretory vesicles and the transcriptional upregulation of GH gene expression, thereby sustaining GH biosynthesis. Additionally, GHRH-R signalling promotes somatotroph cell proliferation through mitogen-activated protein kinase (MAPK) pathway activation, contributing to maintenance of the somatotroph population within the pituitary.
Pulsatile Growth Hormone Secretion
A distinguishing feature of sermorelin-mediated GH release is its preservation of the endogenous pulsatile secretory pattern. Unlike exogenous GH administration, which produces supraphysiological and non-pulsatile elevations in circulating GH concentrations, sermorelin amplifies the amplitude of native GH secretory pulses while maintaining the characteristic ultradian rhythm governed by the hypothalamic GHRH-somatostatin oscillator. This physiological pattern of GH release is subject to negative feedback regulation by both GH itself and insulin-like growth factor I (IGF-I), thereby incorporating an intrinsic safety mechanism against sustained GH excess. Somatostatin, released from periventricular hypothalamic neurons, provides tonic inhibition that gates GHRH-stimulated GH release, ensuring that sermorelin-induced secretion remains responsive to normal homeostatic controls.
Clinical Research in Growth Hormone Deficiency
Paediatric Studies
The principal clinical application investigated for sermorelin has been the treatment of growth hormone deficiency (GHD) in children with intact pituitary somatotroph function. In controlled trials, once-daily subcutaneous administration of sermorelin at doses of 30 μg/kg produced statistically significant increases in growth velocity compared with pre-treatment baselines. Thorner et al. reported that children receiving sermorelin demonstrated a mean first-year growth velocity of 7.0 cm/year, representing a meaningful acceleration from pre-treatment rates (Thorner et al., 1996). A comprehensive review of the clinical data confirmed that sermorelin was most effective in patients with idiopathic GHD who retained residual somatotroph function, as the peptide requires functioning pituitary cells to elicit GH release (Prakash and Goa, 1999).
Importantly, anti-sermorelin antibodies were detected in a proportion of treated subjects during extended administration; however, these antibodies were generally non-neutralising and did not appear to attenuate the growth-promoting response in the majority of cases. The incidence of antibody formation nonetheless represented a clinical consideration during long-term treatment protocols.
Adult and Ageing Populations
Research interest in sermorelin has also encompassed age-related decline in GH secretion, a phenomenon termed somatopause. Vittone et al. conducted a study in healthy elderly men receiving single nightly injections of GHRH(1-29) and observed significant augmentation of nocturnal GH pulse amplitude without alteration of pulse frequency, consistent with the peptide acting to restore diminished GHRH signal strength rather than overriding the hypothalamic timing mechanism (Vittone et al., 1997). Similarly, Corpas et al. demonstrated that continuous subcutaneous infusion of GHRH(1-44) for 14 days in elderly men produced sustained increases in both GH and IGF-I concentrations, supporting the hypothesis that the aged somatotroph retains responsiveness to GHRH stimulation (Corpas et al., 1993). Walker further argued that sermorelin may offer a more physiologically appropriate approach to managing adult-onset GH insufficiency than direct GH replacement, owing to the preservation of feedback regulation (Walker, 2006).
Pharmacokinetics
The pharmacokinetic profile of sermorelin is characterised by rapid absorption following subcutaneous injection, with peak plasma concentrations typically achieved within 5 to 20 minutes. The elimination half-life is notably short, estimated at approximately 10 to 20 minutes in human subjects, reflecting extensive proteolytic degradation by circulating and tissue-bound peptidases (Prakash and Goa, 1999). DPP-IV-mediated cleavage at the N-terminus constitutes the primary degradation pathway, generating the inactive metabolite GHRH(3-29). Additional cleavage sites exist throughout the peptide backbone, contributing to the rapid systemic clearance observed in pharmacokinetic studies.
The short half-life necessitates once-daily or twice-daily administration regimens, and the peak GH response typically occurs 30 to 60 minutes following injection. When administered prior to sleep, sermorelin augments the physiological nocturnal GH surge, which represents the largest secretory episode in the 24-hour cycle. The volume of distribution is relatively small, consistent with limited tissue penetration of the hydrophilic peptide, and renal clearance contributes to the elimination of degradation products.
Comparison With Other GHRH Analogues
The rapid proteolytic degradation of sermorelin prompted the development of modified GHRH analogues with enhanced metabolic stability. CJC-1295, a synthetic GHRH analogue incorporating D-Ala2 substitution (conferring DPP-IV resistance), Gln8 to Ala substitution, and Ala15 to Leu substitution, along with Leu27 to Ser modification, demonstrated substantially prolonged duration of action. When further conjugated to a drug affinity complex (DAC) that enables non-covalent binding to serum albumin, CJC-1295 with DAC achieved an effective half-life of approximately six to eight days in human subjects, permitting once-weekly dosing (Teichman et al., 2006).
In preclinical models, CJC-1295 normalised growth parameters in GHRH knockout mice, demonstrating that the modified analogue retained full GHRH-R agonist activity despite the structural modifications required for protease resistance (Alba et al., 2006). However, the sustained GH elevation produced by CJC-1295 with DAC departs from the pulsatile pattern characteristic of sermorelin and native GHRH, raising questions regarding the physiological fidelity of the GH release profile. The non-DAC form of modified GHRH (often designated CJC-1295 without DAC or Mod GRF 1-29) retains a shorter duration of action more comparable to sermorelin while offering improved resistance to enzymatic degradation.
Tesamorelin, another GHRH analogue consisting of a trans-3-hexenoic acid modification at the N-terminus of GHRH(1-44), received regulatory approval for the reduction of excess abdominal adiposity in HIV-associated lipodystrophy. Compared with sermorelin, tesamorelin exhibits a modestly extended half-life and enhanced potency attributable to its N-terminal protection against aminopeptidase cleavage, while retaining the full-length GHRH(1-44) sequence. These structural distinctions illustrate the broader medicinal chemistry strategy of modifying the GHRH scaffold to optimise pharmacokinetic parameters while preserving receptor selectivity and signalling efficacy.
Current Research Directions
Contemporary research involving sermorelin and related GHRH agonists has expanded beyond classical GHD into several investigational domains. The age-related decline in GH/IGF-I axis activity and its potential contribution to sarcopenia, reduced bone mineral density, altered body composition, and impaired tissue repair has sustained interest in GHRH-based interventions for the ageing population (Corpas et al., 1993). The physiological GH release pattern elicited by GHRH agonists remains a theoretical advantage over direct GH replacement in this context, as feedback-regulated secretion may reduce the risk of sustained GH excess and associated metabolic perturbations.
Preclinical studies have also investigated GHRH receptor agonism in the context of cardiac function, neuroprotection, and wound healing, reflecting the broader tissue distribution of GHRH-R expression beyond the pituitary. Extrapituitary GHRH-R signalling has been implicated in cellular proliferation and survival pathways, suggesting potential applications outside the traditional somatotropic axis. These investigations remain at early stages and have not yet progressed to definitive clinical evaluation.
Additionally, the development of orally bioavailable GHRH receptor agonists represents an active area of pharmaceutical research, motivated by the limitations of injectable peptide administration. Small molecule GHRH-R agonists and non-peptide mimetics are under investigation as potential alternatives that could provide convenient dosing while replicating the receptor-specific signalling of native GHRH and its peptide analogues. The continued refinement of GHRH-based therapeutics underscores the enduring significance of sermorelin as the foundational compound in this pharmacological class (Walker, 2006).